MOTS-c

MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene that activates AMPK to improve glucose uptake, insulin sensitivity, and fatty acid oxidation. It is not FDA-approved, is sold as a research peptide, and is often described as an 'exercise mimetic'.

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded not in nuclear DNA but within the mitochondrial genome itself — specifically in a short open reading frame inside the 12S ribosomal RNA gene. It was identified in 2015 by Changhan David Lee, Pinchas Cohen, and colleagues at the University of Southern California, and reported in Cell Metabolism. Its discovery followed directly from the earlier identification of humanin, the first known mitochondrial-encoded signaling peptide: if the mitochondrial genome contained one such reading frame, the reasoning went, it likely contained others. MOTS-c was the second to be characterized, and the class is now generally called mitochondrial-derived peptides, or MDPs.

What makes MOTS-c conceptually interesting is that it inverts the usual direction of organelle signaling. Mitochondria are normally described as recipients of instruction from the nucleus. MOTS-c is a case of the mitochondrion issuing its own instruction — a peptide it encodes, translated in the cytoplasm, that acts on skeletal muscle metabolism and, under metabolic stress, translocates into the nucleus to alter nuclear gene transcription. Kim and colleagues demonstrated that nuclear translocation in Cell Metabolism in 2018, establishing what is now described as retrograde mitochondrial-to-nuclear signaling.

MOTS-c is popularly marketed as an 'exercise mimetic', and the origin of that label is a real finding rather than a marketing invention: circulating and skeletal-muscle MOTS-c rises with exercise in humans, which is documented in independent studies including von Walden and colleagues in the Journal of Applied Physiology in 2021. But the label overstates what has been shown. Rising with exercise makes MOTS-c an exercise-responsive molecule; it does not establish that administering it reproduces the benefits of exercise in people. That step has not been demonstrated in any published human trial.

The honest position on MOTS-c is that it has an unusually elegant biology and an unusually thin human evidence base. Essentially all efficacy data — insulin sensitization, protection against diet-induced obesity, improved physical capacity, reduced muscle atrophy — comes from mice. The only human interventional data on a MOTS-c-based compound comes from CB4211, an engineered MOTS-c analog developed by CohBar and tested in a completed Phase 1a/1b trial (NCT03998514, 88 participants), not from MOTS-c itself. Compared with the peptides on this site that have completed Phase III programs, MOTS-c is at a much earlier and more speculative stage, and readers should weight it accordingly.

The mechanism originally described by Lee and colleagues in 2015 is metabolic and indirect. MOTS-c acts primarily on skeletal muscle, where it inhibits the folate cycle and the de novo purine biosynthesis pathway tethered to it. Blocking that pathway causes AICAR — 5-aminoimidazole-4-carboxamide ribonucleotide, an intermediate that accumulates when purine synthesis is interrupted — to build up. AICAR is a well-characterized direct activator of AMP-activated protein kinase. So MOTS-c does not bind AMPK; it activates AMPK by perturbing one-carbon metabolism upstream of it. This detail is frequently lost in summaries that simply state 'MOTS-c activates AMPK', and it matters because it predicts effects on cellular methylation capacity that a direct AMPK agonist would not produce.

AMPK is the cell's principal low-energy sensor, and its activation produces the recognizable downstream metabolic profile: increased GLUT4-mediated glucose uptake in skeletal muscle, increased fatty acid oxidation, suppressed lipogenesis and gluconeogenesis, and improved insulin sensitivity. This is the same node that metformin and exercise converge on, which is the mechanistic basis for both the diabetes interest and the exercise-mimetic framing.

The second mechanism is transcriptional. Kim and colleagues showed in 2018 that under metabolic stress — glucose restriction or oxidative stress — MOTS-c translocates from the cytoplasm to the nucleus, where it associates with stress-responsive transcription factors and regulates genes bearing antioxidant response elements, including a broad nuclear stress-response program. This makes MOTS-c a genuine retrograde signal: the mitochondrion communicating its energetic state to the nuclear genome via a peptide it encodes itself.

A more recent third mechanism identifies a direct molecular target. Kumagai and colleagues reported in iScience in 2024 that MOTS-c binds and activates casein kinase 2 (CK2) directly in skeletal muscle. Because CK2 is a pleiotropic kinase, this offers a candidate explanation for muscle-specific effects that the folate-cycle-AICAR-AMPK route does not fully account for, and it partially addresses a longstanding criticism of the field: that MOTS-c was characterized functionally for nearly a decade without a confirmed binding partner. Related work from the same group has linked MOTS-c to reduced myostatin signaling and to suppression of lipid infiltration in immobilized muscle.

One further point of pharmacological uncertainty deserves flagging. MOTS-c's described actions are intracellular — folate-cycle enzymes, nuclear transcription factors, CK2 — yet research protocols administer it subcutaneously. How an exogenous 16-amino-acid peptide reaches the cytoplasm and nucleus of skeletal muscle fibers in sufficient quantity after subcutaneous injection has not been resolved in the published literature, and no human pharmacokinetic study of MOTS-c has been published.

The MOTS-c literature is preclinically rich and clinically almost empty. The distinction to keep in view throughout is between studies of endogenous MOTS-c as a biomarker, which include real human data, and studies of administered MOTS-c as a drug, which are almost entirely rodent.

The founding paper is Lee and colleagues, Cell Metabolism, 2015. It identified the short open reading frame in the mitochondrial 12S rRNA, characterized the 16-amino-acid product, established skeletal muscle as the apparent primary target organ, worked out the folate-cycle and purine-biosynthesis mechanism leading to AMPK activation, and showed that MOTS-c treatment in mice prevented both age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity. Kim and colleagues followed in Cell Metabolism in 2018 with the nuclear translocation and stress-response gene regulation work.

The most-cited aging result is Reynolds and colleagues, Nature Communications, 2021. Mice aged 2, 12, and 22 months were studied, and intermittent MOTS-c treatment at 15 mg/kg three times weekly, initiated late in life at 23.5 months, increased physical capacity and healthspan. The same paper showed that exercise induces endogenous MOTS-c expression in human skeletal muscle and circulation. It is worth being precise about what this does and does not show: it is a healthspan and physical-capacity result in mice, at a dose far above anything used in human research protocols, and it is the strongest single piece of evidence in the field.

Human data exists but is observational and genetic rather than interventional. von Walden and colleagues (Journal of Applied Physiology, 2021) showed that acute endurance exercise raises circulating mitochondrial-derived peptides in humans. Dieli-Conwright and colleagues (Scientific Reports, 2021) examined MOTS-c response to aerobic and resistance exercise in breast cancer survivors. On the genetic side, Fuku and colleagues (Aging Cell, 2015) reported that the m.1382A>C polymorphism, which changes the MOTS-c sequence at position 14 (K14Q), was associated with exceptional longevity in Japanese men — a population-genetics association, not a measurement of circulating peptide levels, and a distinction PeptaHub previously got wrong. Kumagai and colleagues later linked the same K14Q variant to muscle fiber composition and muscular performance.

The muscle literature has been the most productive recent front, largely from Kumagai and colleagues at USC: MOTS-c reduces myostatin and muscle atrophy signaling (American Journal of Physiology, 2021), attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology, 2024), and acts by directly binding and activating CK2 (iScience, 2024). Separate groups have reported effects in gestational diabetes models (Yin and colleagues, Pharmacological Research, 2022), ovarian cancer, pulmonary fibrosis, and lung ischemia-reperfusion injury. All of this is preclinical.

The only human interventional evidence involves an analog rather than MOTS-c itself. CohBar developed CB4211, an engineered MOTS-c analog, and completed a Phase 1a/1b trial (NCT03998514) enrolling 88 participants: a single- and multiple-ascending-dose safety assessment in healthy non-obese adults, followed by a randomized, double-blind, placebo-controlled evaluation of 25 mg once daily by subcutaneous injection for four weeks in obese subjects with non-alcoholic fatty liver disease. The company reported in August 2021 that the study met its primary endpoint — CB4211 was well tolerated with no serious adverse events — and that exploratory pharmacodynamic endpoints showed significant reductions in ALT and AST, a significant decrease in glucose, and a trend toward lower body weight. These are topline results for a modified analog in a small early-phase study, reported by the sponsor; they are not peer-reviewed efficacy evidence, and they do not transfer to unmodified MOTS-c sold as a research chemical.

No human pharmacokinetic study of MOTS-c has been published, so the widely quoted ~4 hour half-life and the 5-10 mg dosing figures in circulation are not derived from human data. Given that CB4211's clinical dose was 25 mg daily for an optimized analog, the relationship between research-chemical protocols and anything clinically characterized is unclear.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]

Peptides commonly paired with MOTS-c for synergistic effects.